115290-77-2

Upstream product

• 5764-85-2 Ethyl 3-hydroxy-3-phenylpropanoate 
• 33401-74-0 ethyl (3R)-3-hydroxy-3-phenylpropionate 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 98819-68-2 3-phenyl-(2R,3R)-oxiran-2-ylmethanol 
• 100-52-7 benzaldehyde 
• 838841-85-3 (3S) ethyl β-butyryloxy-β-phenyl propionate 
• 118856-08-9 butyric acid 2-ethoxycarbonyl-1-phenyl-ethyl ester 
• 96854-34-1 (S)-3-phenyl-1,3-propanediol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 138110-76-6 (R)-3-(4-trifluoromethylphenoxy)-3-phenylprop-1-yl methanesulfonate 
• 138110-77-7 (R)-3-Iodo-3-(4-trifluoromethylphenoxy)propane 
• 114247-06-2 (S)-fluoxetine hydrochloride 
• 114247-09-5 (R)-fluoxetine hydrochloride 
• 54910-89-3 (R)-fluoxetine 
• 114133-37-8 (S)-N-methyl-3-amino-1-phenyl-1-propanol 
• 82248-59-7 atomoxetine hydrochloride 
• 100568-02-3 (S)-fluoxetine 
• 105314-52-1 (R)-tomoxetine 
• 115290-79-4 (R)-3-(2-methylphenoxy)-3-phenylprop-1-yl methanesulfonate 
• 114133-36-7 (S)-(-)-3-iodo-1-phenyl-1-propanol 

Relevant academic research and scientific papers

Candida Rugosa lipase-catalyzed kinetic resolution of β-hydroxy- β-arylpropionates and δ-hydroxy-δ-aryl-β-oxo-pentanoates

A simple and convenient method was reported for the preparation of optically active β-hydroxy-β-arylpropionates, δ-hydroxy-δ- aryl-β-oxo-pentanoates and their butyryl derivatives via CRL-catalyzed hydrolysis. The optically active products are potential precursors of some chiral pharmaceuticals and natural products.

Pure S(+)isomer fluoxetine

Methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of unwanted, adverse toxic or psychological effects, for the treatment of human depression. In addition, methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is useful in treating migraine headaches, pain, in particular chronic pain, and obsessive-compulsive disorders. Further, methods and compositions for treating a condition alleviated or improved by inhibition of serotonin uptake in serotonergic neurons and platelets in a human using optically pure S(+) fluoxetine are disclosed.

Asymmetric Synthesis of Both Enantiomers of Fluoxetine via Microbiological Reduction of Ethyl Benzoylacetate

Microbiological reduction of ethyl benzoylacetate by bakers' yeast (Saccharomyces cerevisiae), Beauveria sulfurescens or Geotrichum candidum afforded ethyl (S)-3-hydroxy-3-phenylpropionate in high optical yield.This enantiomerically pure alcohol was converted into both enantiomers of fluoxetine (7).The product resulting from the bakers' yeast reduction had ee values (87-93percent) lower than the 100percent value erroneously attributed in earlier studies.Key Words: Fluoxetine; asymmetric synthesis; bioreduction; bakers' yeast; Beauveria sulfurescens; Geotrichum candidum.

Chemoenzymatic Synthesis of Both Enantiomers of Fluoxetine

Both enantiomers of fluoxetine have been synthesized from ethyl benzoylacetate.The key step is the enantioselective reduction of the starting material by baker's yeast.

Asymmetric Synthesis of Both Enantiomers of Tomoxetine and Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-Al.

Both enantiomers of tomoxetine 7a,7b and fluoxetine 8a,8b (as their hydrochloride salts) have been synthetized from cinnamyl alkohol by asymmetric epoxidation, and their absolute configurations have been established.Optimal conditions for regioselective Red-Al reduction at C-2 of 2,3-epoxycinnamyl alcohol are discussed.